Direction to the Independent Hospital Pricing Authority on the performance of its functions under section 226 of the National Health Reform Act 2011 - No. 1/2014 (Cth)

Direction to the Independent Hospital Pricing Authority on the performance of its functions under section 226 of the National Health Reform Act 2011 - No. 1/2014

I, PETER DUTTON, Minister for Health, acting under subsection 226(1) of the National Health Reform Act 2011 (the Act), having consulted with the Standing Council on Health, DIRECT that the Independent Hospital Pricing Authority make the determination set out in Item 1 of the Schedule to this instrument, and have regard to the matters set out in Item 2 of the Schedule to this instrument.

Dated: 19th December 2014

PETER DUTTON Minister for Health

Contents

PART 1 PRELIMINARY 3

1 Name of Direction 3 2. Commencement 3 3. Authority 3 4. Definition 3 5. Schedule 3

Schedule 4

Part 1 Preliminary

1. Name of Direction

This Instrument is the Direction to the Independent Hospital Pricing Authority on the performance of its functions under section 226 of the National Health Reform Act 2011 - No. 1/2014.

2. Commencement

This Direction takes effect on the day after it is registered on the Federal Register of Legislative Instruments.

3. Authority

This Direction is made under the National Health Reform Act 2011.

4. Definition

In this Direction: refined list of standard items means the list provided by the Department of Health, having received it from the National Health and Medical Research Council, based on list devised in 2012 that was subsequently reviewed in 2014.

5. Schedule

The Schedule to this Instrument describes the direction given to the Independent Hospital Pricing Authority on the performance of its functions.

Schedule

1. Functions

(i) By 30 June 2015, the Independent Hospital Pricing Authority, in relation to its function under s. 131(1)(a) of the Act must determine the costs for the refined list of items and any other items (above those costs required for standard care), as determined necessary by the Independent Hospital Pricing Authority, associated with conducting clinical trials in Australia.